Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et...

por Song, Jinlin, Gao, Wei, Xie, Jipan, Tiwana, Simran
Publicado 2019

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA...

por Priyadarshini, Masoom, Deshpande, Gaurav, Tiwana, Simran K, Le, T. Kim, Garrison, Sean, Awan, Farrukh
Publicado 2023

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYM...

por Priyadarshini, Masoom, Balantac, Zaneta, Tiwana, Simran K, Bapat, Shweta S, Garrison, Sean, Martin, Mona L
Publicado 2023